Skip directly to content

Sutent®

Sutent® proactively antagonizes the metastatic problems with proliferative renal cell, gastrointestinal stromal cell and pancreatic neuroendocrine cell.1 Approved by FDA and with recommendation by NICE(UK) guideline2, Sutent® has been enlisted as subsidized medical treatment against two specific diseases by the Community Care Fund.3

Reference:

  1. Sutent® (sunitinib malate) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version May 2015.
  2. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 169. March 2009.
  3. Items supported by the Samaritan Fund and Community Care Fund Medical Assistance Programme. Hong Kong Hospital Authority. Accessed on 6 June 2019. Available at https://www.ha.org.hk/visitor/ha_visitor_index.asp?content_id=208076#.

[PP-CPF-HKG-0070] SEP 2019

Therapeutic Area Sub Category: